Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
← catalyst calendarSponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →. With Medpace, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-13 | actual | When the study began enrolling |
| Primary completion | 2026-04-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Brain Metastases From Solid Tumors
Intervention
- Drug: RAD101 (18F-FPIA)
Primary outcomes
what the primary-completion date above is the date OFConcordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium
measured 1 Week
Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium
measured 1 Week
Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium
measured 1 Week
Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed